Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
25.47 ^USD	-2.86%		+1.92%	-13.72%

05-10	Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating	MT
05-08	Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024

Mirum Pharmaceuticals, Inc. Announces Resignation of Edward T. Mathers as A Member of the Compensation Committee of the Board, Effective September 1, 2022

September 02, 2022 at 09:31 pm

On September 1, 2022, Edward T. Mathers notified the board of directors of Mirum Pharmaceuticals, Inc. of his resignation as a director of the Company and as a member of the Compensation Committee of the Board, effective September 1, 2022.

Latest news about Mirum Pharmaceuticals, Inc.

Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating	05-10	MT
Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q1 Revenue $69.2M, vs. Street Est of $70.2M	05-08	MT
Mirum Pharmaceuticals, Inc Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC	05-07	CI
Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target	04-17	MT
Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome	04-02	CI
JMP Securities Raises Price Target on Mirum Pharmaceuticals to $72 From $69, Maintains Market Outperform Rating	03-14	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	03-14	MT
Sector Update: Health Care	03-14	MT
HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $58 From $45, Maintain Buy Rating	03-14	MT
Mirum Pharmaceuticals Says FDA Approved Familial Intrahepatic Cholestasis Treatment	03-14	MT
Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli	03-13	DJ
US FDA approves expanded use of Mirum's liver disease drug	03-13	RE
Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis	03-13	CI
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $40 From $35, Maintains Overweight Rating	03-04	MT
Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024	02-28	CI
Transcript : Mirum Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q4 Revenue $69.6M, vs. Street Est of $67.9M	02-28	MT
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28	CI
Mirum Pharmaceuticals, Inc. Announces Management Changes	01-16	CI
Mirum Pharmaceuticals Names Joanne Quan as Chief Medical Officer	01-16	MT
Mirum Pharmaceuticals, Inc. Announces Management Appointments	01-16	CI
Transcript : Mirum Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM	01-10
Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023	01-08	CI

Chart Mirum Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Mirum Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.22 USD

Average target price

48 USD

Spread / Average Target

+83.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MIRUM PHARMACEUTICALS, INC.	-13.72%	1.24B
MODERNA, INC.	+64.92%	62.59B
IQVIA HOLDINGS INC.	-1.85%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	19.09B
BIO-TECHNE CORPORATION	+4.21%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.26B
MEDPACE HOLDINGS, INC.	+27.42%	12.05B

Other Biotechnology & Medical Research